Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.
Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlaczek O, Stenzinger A, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfeld C, Ungerechts G. Hajda J, et al. Among authors: stenzinger a. BMC Cancer. 2017 Aug 29;17(1):576. doi: 10.1186/s12885-017-3604-y. BMC Cancer. 2017. PMID: 28851316 Free PMC article. Clinical Trial.
Mutations in BRCA2 and taxane resistance in prostate cancer.
Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S. Nientiedt C, et al. Among authors: stenzinger a. Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x. Sci Rep. 2017. PMID: 28676659 Free PMC article.
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.
Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S. Dietz S, et al. Among authors: stenzinger a. Oncotarget. 2017 May 23;8(43):74049-74057. doi: 10.18632/oncotarget.18200. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088767 Free PMC article.
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
Muckenhuber A, Berger AK, Schlitter AM, Steiger K, Konukiewitz B, Trumpp A, Eils R, Werner J, Friess H, Esposito I, Klöppel G, Ceyhan GO, Jesinghaus M, Denkert C, Bahra M, Stenzinger A, Sprick MR, Jäger D, Springfeld C, Weichert W. Muckenhuber A, et al. Among authors: stenzinger a. Clin Cancer Res. 2018 Jan 15;24(2):351-359. doi: 10.1158/1078-0432.CCR-17-2180. Epub 2017 Nov 3. Clin Cancer Res. 2018. PMID: 29101303
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.
Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H. Heining C, et al. Among authors: stenzinger a. Cancer Discov. 2018 Sep;8(9):1087-1095. doi: 10.1158/2159-8290.CD-18-0036. Epub 2018 May 25. Cancer Discov. 2018. PMID: 29802158
Prostatic metastasis from intrahepatic cholangiocarcinoma.
Tosev G, Schuetz V, Nyarangi-Dix J, Stenzinger A, Stoegbauer F, Kulu Y, Radtke JP, Teber D, Hatzinger M, Springfeld C, Koehler BC, Hohenfellner M. Tosev G, et al. Among authors: stenzinger a. Urol Case Rep. 2018 Jul 18;20:90-91. doi: 10.1016/j.eucr.2018.07.015. eCollection 2018 Sep. Urol Case Rep. 2018. PMID: 30101074 Free PMC article. No abstract available.
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.
Kirchner M, Neumann O, Volckmar AL, Stögbauer F, Allgäuer M, Kazdal D, Budczies J, Rempel E, Brandt R, Talla SB, von Winterfeld M, Leichsenring J, Bochtler T, Krämer A, Springfeld C, Schirmacher P, Penzel R, Endris V, Stenzinger A. Kirchner M, et al. Among authors: stenzinger a. Cancers (Basel). 2019 Sep 5;11(9):1309. doi: 10.3390/cancers11091309. Cancers (Basel). 2019. PMID: 31491926 Free PMC article.
The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. Jenzer M, et al. Among authors: stenzinger a. Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23. Cancer Immunol Immunother. 2019. PMID: 31549213 Free PMC article.
480 results